Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,350,4242,DB01101,Capecitabine
,23595344,maximum tolerated dose,"The maximum tolerated dose of irinotecan was 350 mg/m(2) for the 0 and 1 DA groups, and 200 mg/m(2) for the 2 DA group.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,200,4243,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,7.72,4244,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,5.71,4245,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,2.72,4246,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,85,4247,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,83,4248,DB01101,Capecitabine
,23595344,AUClast ratios,"For the 0, 1, and 2 DA groups, mean AUClast ratios of SN-38G to SN-38 were 7.72, 5.71, and 2.72 (P = 0.0023) and relative dose intensities at recommended dose were 85, 83, and 97 %.",A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23595344/),,97,4249,DB01101,Capecitabine
,24820348,RD,The RD for the phase II study was thus determined to be 90 mg/m(2).,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),[mg] / [m],90,5602,DB01101,Capecitabine
,24820348,response rate,The response rate was 41.7%.,A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24820348/),%,41.7,5603,DB01101,Capecitabine
,24556590,T1/2β,"(131)I-huA33 demonstrated a mean terminal half-life and serum clearance suited to radioimmunotherapy (T1/2β, 100.24 ± 20.92 h, and clearance, 36.72 ± 8.01 mL/h).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),h,100.24,5825,DB01101,Capecitabine
,24556590,clearance,"(131)I-huA33 demonstrated a mean terminal half-life and serum clearance suited to radioimmunotherapy (T1/2β, 100.24 ± 20.92 h, and clearance, 36.72 ± 8.01 mL/h).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),[ml] / [h],36.72,5826,DB01101,Capecitabine
,24556590,total tumor dose,"The mean total tumor dose was 13.8 ± 7.6 Gy (range, 5.1-26.9 Gy).",Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556590/),gy,13.8,5827,DB01101,Capecitabine
,9586893,MTD,"The MTD was 1,657 mg/m2/d with limiting toxicities of palmar-plantar erythrodysesthesia, nausea, vomiting, vertigo, abdominal pain, diarrhea, and thrombocytopenia.",Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9586893/),[mg] / [d·m2],"1,657",5941,DB01101,Capecitabine
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,892,10721,DB01101,Capecitabine
,18414865,AUC,"Among patients treated with a constant capecitabine dose of 450 mg bid, there was a higher mean AUC of 5-FU in women than in men (mean +/- SD: 892 +/- 287 nM h vs. 537 +/- 182 nM h; Mann-Whitney two-tailed, P = 0.02).","Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18414865/),h·nM,537,10722,DB01101,Capecitabine
,21339064,response duration,"The median response duration was 3.1 months (95% CI: 2.1-8.4 months), with four of five lasting for more than 3 months.",A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21339064/),month,3.1,17771,DB01101,Capecitabine
,21339064,time to progression,Median time to progression was 4.9 months.,A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21339064/),month,4.9,17772,DB01101,Capecitabine
,19238629,Objective response rates,"Objective response rates of 65% (95% confidence interval (CI): 43-82), disease stabilisation of 25% (95% CI: 11-47) and a disease control rate (CR + PR + SD) of 90% were achieved overall.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),%,65,18433,DB01101,Capecitabine
,19238629,MTD,"The MTD of matuzumab in combination with ECX was 800 mg weekly, and at this DL it was well-tolerated and showed encouraging antitumour activity.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),mg,800,18434,DB01101,Capecitabine
,26435217,maximum concentration,Thymine peaked quickly (30-45min) in plasma to a maximum concentration of 170±185μg/L (mean±SD).,Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26435217/),[μg] / [l],170,22031,DB01101,Capecitabine
,26435217,Clearance,"Clearance was high (mean 57.9L/h/kg) exceeding normal human liver blood flow, suggesting low systemic bioavailability; urinary recovery of the thymine dose was low (<1%).",Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26435217/),[l] / [h·kg],57.9,22032,DB01101,Capecitabine
,20857171,MTD,"The MTD of single-agent oral irinotecan was estimated to be 60 mg/m(2)/day, and DLT included diarrhea, nausea, and neutropenia.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),mg,60,25570,DB01101,Capecitabine
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],40,25571,DB01101,Capecitabine
,20857171,MTD,"In an initial group of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, the MTD of sequential oral irinotecan/capecitabine was estimated to be 40/1600 mg/m(2)/day with DLT of delayed diarrhea.",Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20857171/),[mg] / [d·m(2)],1600,25572,DB01101,Capecitabine
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],0.26,30305,DB01101,Capecitabine
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],2.66,30306,DB01101,Capecitabine
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],4.22,30307,DB01101,Capecitabine
,12618890,c(max),"As intended with the prodrug design of capecitabine, FU was present in low concentrations in tumour interstitium (median c(max): 0.26 microg ml(-1)) when compared with capecitabine, DFCR, and DFUR (median c(max): 2.66, 4.22, and 2.13 microg ml(-1), respectively).",Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12618890/),[μg] / [ml],2.13,30308,DB01101,Capecitabine
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,3.83,30470,DB01101,Capecitabine
,29798953,PFS,The median PFS at 1 year was 3.83 months in test arm and 4.6 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,4.6,30471,DB01101,Capecitabine
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,10.91,30472,DB01101,Capecitabine
,29798953,OS,The mean OS was 10.91 months in test arm and 14.68 months in reference arm.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),month,14.68,30473,DB01101,Capecitabine
,29798953,Tmax,The median Tmaxwas 6.00 h in both the arms.,"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,6.00,30474,DB01101,Capecitabine
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,330.63,30475,DB01101,Capecitabine
,29798953,t½,"The median t½ was 330.63 h and 226.14 h, respectively, for test and reference bevacizumab.","Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29798953/),h,226.14,30476,DB01101,Capecitabine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,67,38013,DB01101,Capecitabine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,0,38014,DB01101,Capecitabine
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,56,38015,DB01101,Capecitabine
,18765554,conversion,The conversion of capecitabine to 5-fluorouracil was higher for the combination of EKB-569 and capecitabine (321+/-151 ng*h/mL) than for capecitabine alone (176+/-62 ng*hours/mL; P=0.0037).,A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765554/),[h·ng] / [ml],321,38113,DB01101,Capecitabine
,18765554,conversion,The conversion of capecitabine to 5-fluorouracil was higher for the combination of EKB-569 and capecitabine (321+/-151 ng*h/mL) than for capecitabine alone (176+/-62 ng*hours/mL; P=0.0037).,A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765554/),[h·ng] / [ml],176,38114,DB01101,Capecitabine
,24013904,progression-free survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,11.0,45577,DB01101,Capecitabine
,24013904,overall survival,"At a median follow-up of 106 weeks (range, 21-141 weeks), the median progression-free survival and overall survival were 11.0 weeks (95% C.I.: 5.7-16.3 weeks) and 21.0 weeks (95% C.I.: 14.3-27.7 weeks), respectively.",Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013904/),weeks,21.0,45578,DB01101,Capecitabine
,31658382,THY/DHT,"The median THY/DHT ratios were 6.2 (interquartile range 2.9-6.4) in cases, including the 2 patients who were DPYD heterozygous carriers.",A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31658382/),,6.2,51207,DB01101,Capecitabine
,31658382,ratios,"The median THY/DHT ratios were 6.2 (interquartile range 2.9-6.4) in cases, including the 2 patients who were DPYD heterozygous carriers.",A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31658382/),,6.2,51208,DB01101,Capecitabine
,23108953,PFS,"Median estimated PFS in Arms A, B, and C was 4.2, 4.9, and 5.2 months, respectively (hazard ratio for Arms A+B combined versus Arm C, 0.98; 95% CI 0.67-1.43; P = 0.92).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),,4,51541,DB01101,Capecitabine
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,27,51542,DB01101,Capecitabine
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,43,51543,DB01101,Capecitabine
,23108953,Objective response rates,"Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C).","Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108953/),%,35,51544,DB01101,Capecitabine
,26499900,overall response rate,The overall response rate was 45 %; two patients achieved a complete response.,"Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),%,45,59541,DB01101,Capecitabine
,26499900,progression-free survival,"Median progression-free survival and overall survival were 6.5 months (95 % CI 5.4-7.6) and 11.0 months (95 % CI 7.9-14.1), respectively.","Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),month,6.5,59542,DB01101,Capecitabine
,26499900,overall survival,"Median progression-free survival and overall survival were 6.5 months (95 % CI 5.4-7.6) and 11.0 months (95 % CI 7.9-14.1), respectively.","Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26499900/),month,11.0,59543,DB01101,Capecitabine
,24942210,clearance,Median bevacizumab clearance in AGC was 4.5 versus 3 mL/day/kg in other cancers.,Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24942210/),[ml] / [d·kg],4.5,61751,DB01101,Capecitabine
,24942210,clearance,Median bevacizumab clearance in AGC was 4.5 versus 3 mL/day/kg in other cancers.,Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24942210/),[ml] / [d·kg],3,61752,DB01101,Capecitabine
,16825251,overall response rate,"The overall response rate was 35% [95% confidence interval (CI), 23-48%], and 52% of patients had stable disease.",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),%,35,65409,DB01101,Capecitabine
,16825251,time to progression,"The median time to progression was 5.5 months (95% CI, 4.2-6.7 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,5.5,65410,DB01101,Capecitabine
,16825251,overall survival,"The median overall survival was 20.2 months (95% CI, 16.6-27.8 months).",A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16825251/),month,20.2,65411,DB01101,Capecitabine
>,18077151,cytotoxicity ratios,Cell lines with low CDD expression (<1.5) had 5'DFCR/5'DFUR cytotoxicity ratios>2 and cell lines with TP/DPD<0.6 had 5'DFUR IC50>50 microM (SRB assay).,"Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18077151/),,2,66874,DB01101,Capecitabine
>,18077151,IC50,Cell lines with low CDD expression (<1.5) had 5'DFCR/5'DFUR cytotoxicity ratios>2 and cell lines with TP/DPD<0.6 had 5'DFUR IC50>50 microM (SRB assay).,"Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18077151/),μM,50,66875,DB01101,Capecitabine
,23589214,elimination half-life,Mean elimination half-life of LBY135 ± capecitabine at saturation of clearance (≥10 mg/kg) ranged between 146 h and 492 h.,"Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589214/),h,146,67313,DB01101,Capecitabine
,23589214,elimination half-life,Mean elimination half-life of LBY135 ± capecitabine at saturation of clearance (≥10 mg/kg) ranged between 146 h and 492 h.,"Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23589214/),h,492,67314,DB01101,Capecitabine
,16778105,number,"The median number of cycles administered per patient was 2.0 (range, 1-12) in part I and 2.0 (range, 1-13) in study part II.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),,2.0,73924,DB01101,Capecitabine
,16778105,number,"The median number of cycles administered per patient was 2.0 (range, 1-12) in part I and 2.0 (range, 1-13) in study part II.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),,2.0,73925,DB01101,Capecitabine
,16778105,MTD,"The MTD was 30 mg/m(2)/d for irinotecan single agent and 30/1,600 mg/m(2)/d for the combination with capecitabine.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),[mg] / [d·m(2)],30,73926,DB01101,Capecitabine
,16778105,MTD,"The MTD was 30 mg/m(2)/d for irinotecan single agent and 30/1,600 mg/m(2)/d for the combination with capecitabine.",Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778105/),[mg] / [d·m(2)],"1,600",73927,DB01101,Capecitabine
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,21,77038,DB01101,Capecitabine
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,35,77039,DB01101,Capecitabine
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,56,77040,DB01101,Capecitabine
,30592773,molar ratio,The molar ratio tended to increase within 1.5 h (1.85 ± 0.76 at 1.5 h after administration of capecitabine) and gradually recovered to its initial level (1.00 ± 0.46).,Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592773/),,1.85,78391,DB01101,Capecitabine
,30592773,molar ratio,The molar ratio tended to increase within 1.5 h (1.85 ± 0.76 at 1.5 h after administration of capecitabine) and gradually recovered to its initial level (1.00 ± 0.46).,Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592773/),,1.00,78392,DB01101,Capecitabine
,10550565,t(max),There was no clinically significant difference between the t(max) for the two formulations (median 2.1 versus 2.0 h).,"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),h,2.1,80078,DB01101,Capecitabine
,10550565,t(max),There was no clinically significant difference between the t(max) for the two formulations (median 2.1 versus 2.0 h).,"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),h,2.0,80079,DB01101,Capecitabine
,10550565,overall urinary excretions,"The overall urinary excretions were 86.0% and 86.5% of the dose, respectively, and the proportion recovered as each metabolite was similar for the two formulations.","Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550565/),,86,80080,DB01101,Capecitabine
,22648745,MTD,"The MTD of capecitabine was 4,500 mg.",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),mg,"4,500",80187,DB01101,Capecitabine
,22648745,objective response rate,"The objective response rate was 33.3 %, and median overall survival was 16.3 months (95 % CI: 11.2-18.2 months).",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),%,33.3,80188,DB01101,Capecitabine
,22648745,overall survival,"The objective response rate was 33.3 %, and median overall survival was 16.3 months (95 % CI: 11.2-18.2 months).",Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22648745/),month,16.3,80189,DB01101,Capecitabine
,19861447,standardized uptake,"The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively.",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[m(2] / [ml],11.11 x 10(-5),88499,DB01101,Capecitabine
,19861447,unit impulse response function,"The baseline average standardized uptake value at 60 minutes, rate constant for the net irreversible transfer of radiotracer from plasma to tumor (Ki), and unit impulse response function at 60 minutes were 11.11 x 10(-5) m(2)/mL, 4.38 x 10(-2) mL plasma/min/mL tissue, and 4.93 x 10(-2)/min, respectively.",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),,4.93 x 10(-2),88500,DB01101,Capecitabine
,19861447,standardized uptake,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[m(2] / [ml],13.55 x 10(-5),88501,DB01101,Capecitabine
,19861447,Ki,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),[ml·plasma] / [min·ml·tissue],7.40 x 10(-2),88502,DB01101,Capecitabine
,19861447,impulse response function,"One hour after capecitabine administration, the standardized uptake value was 13.55 x 10(-5) m(2)/mL (P = 0.004), Ki 7.40 x 10(-2) mL plasma/min/mL tissue (P = 0.004), and impulse response function was 7.40 x 10(-2)/min (P = 0.002).",Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861447/),,7.40 x 10(-2),88503,DB01101,Capecitabine
,15844007,AUC,Median daily 5'-DFUR AUC was significantly higher for capecitabine than for 5'-DFUR (81.1 vs 32.6 mmol h/l; P = 0.01).,"Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·mM] / [l],81.1,91400,DB01101,Capecitabine
,15844007,AUC,Median daily 5'-DFUR AUC was significantly higher for capecitabine than for 5'-DFUR (81.1 vs 32.6 mmol h/l; P = 0.01).,"Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·mM] / [l],32.6,91401,DB01101,Capecitabine
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],3.83,91402,DB01101,Capecitabine
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],6.46,91403,DB01101,Capecitabine
,15844007,AUC,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],2.53,91404,DB01101,Capecitabine
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],4.88,91405,DB01101,Capecitabine
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],4.96,91406,DB01101,Capecitabine
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[h·μg] / [ml],2.53,91407,DB01101,Capecitabine
,15844007,Cmax,"Following treatment with 5'-DFUR, the median AUC and Cmax of 5'-DFUR tended to be higher in patients with a partial response (3.83 microg h/ml and 4.88 microg/ml) and stable disease (6.46 microg h/ml and 4.96 microg/ml) than in those with disease progression (2.53 microg h/ml and 1.36 microg/ml).","Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15844007/),[μg] / [ml],1.36,91408,DB01101,Capecitabine
,16284918,K(a),"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],2.1,92790,DB01101,Capecitabine
,16284918,lag time,"Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable.",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),h,0.28,92791,DB01101,Capecitabine
,16284918,CL (CL10,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),[l] / [h],218,92792,DB01101,Capecitabine
,16284918,elimination rate constant (K34,"The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT).",Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],5.3,92793,DB01101,Capecitabine
,16284918,elimination rate constant of plasma 5-FU (K40),The elimination rate constant of plasma 5-FU (K40) was 66 +/- 24 hr(-1) (ISV = 34%).,Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284918/),1/[hr],66,92794,DB01101,Capecitabine
,29161913,particle size,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),µm,494.37,92951,DB01101,Capecitabine
,29161913,% drug entrapment,"The particle size and % drug entrapment of the optimized batch was 494.37 ± 1.4 µm and 81.39 ± 2.9%, respectively, closer to the value predicted by Minitab 17 software.",Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29161913/),%,81.39,92952,DB01101,Capecitabine
,18249110,Overall response rate,"Overall response rate was 67%, comprising two complete and 12 partial responders in 21 assessable patients.",Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18249110/),%,67,95867,DB01101,Capecitabine
,25687989,clearance,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),[l] / [d],0.18,102885,DB01101,Capecitabine
,25687989,elimination rate constant,"The estimated clearance of bevacizumab was 0.18 L/day, the free VEGF165 levels at baseline were 212 ng/L, and the elimination rate constant of free VEGF165 was 0.401 day(-1).",A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687989/),1/[day],0.401,102886,DB01101,Capecitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,50,109626,DB01101,Capecitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,75,109627,DB01101,Capecitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,100,109628,DB01101,Capecitabine
,23235319,Dose levels (DLs),"Dose levels (DLs) 1, 2, 3 and 4 were 50, 75, 100 and 125 mg/day, respectively.",Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23235319/),,125,109629,DB01101,Capecitabine
,23852665,maximum tolerated dose,First-in-man phase I study set the maximum tolerated dose at 3.6 mg/kg given intravenously on a 3-weekly regimen.,"The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23852665/),,3,110307,DB01101,Capecitabine
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],366,111241,DB01101,Capecitabine
,24114122,AUCs,"UGT1A1 *1/*28 and *1/*1 patients treated with IRIN (150) had similar AUCs for the active irinotecan metabolite, SN38 (366 +/- 278 and 350 +/- 159 ng/ml*hr, respectively).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],350,111242,DB01101,Capecitabine
,24114122,exposures,"UGT1A1 *28/*28 patients (n = 3) treated with a lower IRIN dose (100) had non-significantly higher mean SN38 exposures (604 +/- 289 ng/ml*hr, p = 0.14).","UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24114122/),[ng] / [h·ml],604,111243,DB01101,Capecitabine
,12196374,overall survival,"Of 29 patients with evaluable disease, there was one complete response and six partial responses [24% response rate [95% confidence interval (CI) 10% to 44%]], a median PFS of 22 weeks (95% CI 17-27 weeks) and median overall survival of 34 weeks (95% CI 19-49 weeks).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),weeks,34,117162,DB01101,Capecitabine
,12196374,t(max),"Capecitabine was rapidly absorbed after oral administration, with a t(max) of 1-2 h for capecitabine, DFCR (5'-deoxy-5-fluorocytidine) and DFUR (5'-deoxy-5-fluorouridine).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),h,1-2,117163,DB01101,Capecitabine
,22045498,response rate,"Objective partial responses were reported in 7 patients, yielding a response rate of 43.8% in the all-treated population according to the investigator assessment.",A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22045498/),%,43.8,118154,DB01101,Capecitabine
,29493289,zeta potential,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),m,26.9,125351,DB01101,Capecitabine
,29493289,entrapment efficiency,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),m,26.9,125352,DB01101,Capecitabine
,29493289,entrapment efficiency,"The optimized nanoparticles have the particle size, zeta potential, and entrapment efficiency of 145.6 ± 3.6 nm, -26.9 ± 2.7 mV, and 88.33 ± 3.74%, respectively.","Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29493289/),%,88.33,125353,DB01101,Capecitabine
,25957957,clearance [CL,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[l] / [h],51.7,127698,DB01101,Capecitabine
,25957957,clearance [CL,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[l] / [h],46.7,127699,DB01101,Capecitabine
,25957957,area under the curve [AUC0-220min,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[h·mg] / [l],20.6,127700,DB01101,Capecitabine
,25957957,area under the curve [AUC0-220min,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),[h·mg] / [l],21.0,127701,DB01101,Capecitabine
,25957957,elimination half-life [t 1/2,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,21,127702,DB01101,Capecitabine
,25957957,elimination half-life [t 1/2,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,21,127703,DB01101,Capecitabine
,25957957,maximum concentration time [T max,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,27,127704,DB01101,Capecitabine
,25957957,maximum concentration time [T max,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),min,25,127705,DB01101,Capecitabine
,25957957,volume of distribution [V,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),l,26.58,127706,DB01101,Capecitabine
,25957957,volume of distribution [V,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),l,21.10,127707,DB01101,Capecitabine
,25957957,elimination constant [k el,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),1/[h],2.01,127708,DB01101,Capecitabine
,25957957,elimination constant [k el,"The mean uracil clearance [CL 51.7 (SD 6.4) vs. 46.7 (SD 13.0) l/h], area under the curve [AUC0-220min 20.6 (SD 6.4) vs. 21.0 (SD 5.7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs. 21 (SD 8) min], maximum concentration time [T max 27 (SD 9) vs. 25 (SD 9) min], volume of distribution [V 26.58 (SD 10.11) vs. 21.10 (SD 8.48) l] and the elimination constant [k el 2.01 (SD 0.56) vs. 2.41 (SD 0.72) h(-1)] did not differ significantly (p > 0.05) non-metastatic CRD versus metastatic CRC.",Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25957957/),1/[h],2.41,127709,DB01101,Capecitabine
,28667466,overall response rate,"Among the 11 patients with measurable disease, overall response rate and disease control rate were 45.5% and 100.0%, respectively.","Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),%,45.5,133613,DB01101,Capecitabine
,28667466,disease control rate,"Among the 11 patients with measurable disease, overall response rate and disease control rate were 45.5% and 100.0%, respectively.","Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),%,100.0,133614,DB01101,Capecitabine
,28667466,progression-free survival,Median progression-free survival (95% CI) was 7.6 months (6.0 to not estimable).,"Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667466/),month,7.6,133615,DB01101,Capecitabine
,27538461,drug,"Capecitabine, an anti cancer drug, has a very short drug elimination half-life (0.49 to 0.89 h).",Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538461/),h,0.49 to 0.89,133773,DB01101,Capecitabine
,27538461,elimination half-life,"Capecitabine, an anti cancer drug, has a very short drug elimination half-life (0.49 to 0.89 h).",Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538461/),h,0.49 to 0.89,133774,DB01101,Capecitabine
,16062072,AUC,"Patients received carboplatin (AUC = 2) on days 1 and 8, docetaxel (35-40 mg/m2) on days 1 and 8, and capecitabine (500-2000 mg/m2) on days 1 to 10.","Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16062072/),,2,134671,DB01101,Capecitabine
,16062072,AUC,"The MTD was docetaxel, 40 mg/m2 days 1 and 8; carboplatin, AUC = 2 days 1 and 8; and capecitabine, 1500 to 2000 mg/m2 days 1 to 10 in a 21-day cycle.","Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16062072/),,2,134672,DB01101,Capecitabine
,15729602,MTD,The MTD of continuous oral capecitabine over 6 weeks was 1255 mg/m2 twice daily.,A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729602/),[mg] / [m2],1255,138416,DB01101,Capecitabine
,21409383,t (½),The V (ss) and CL did not differ between the two regimens; t (½) during the PK cycle was also similar for both arms at approximately 16 days.,"A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21409383/),d,16,141601,DB01101,Capecitabine
,27325685,PFS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,3.3,143563,DB01101,Capecitabine
,27325685,PFS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,6.3,143564,DB01101,Capecitabine
,27325685,OS,"Median PFS and OS were 3.3 and 6.3 months, respectively.",A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27325685/),month,6.3,143565,DB01101,Capecitabine
,15866500,Retention times,"Retention times were 7.5 and 12.5 min for 2'-deoxyuridine and 5-iodo-2'-deoxyuridine, an iodinated analogue internal standard (IS), respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),min,7.5,147463,DB01101,Capecitabine
,15866500,Retention times,"Retention times were 7.5 and 12.5 min for 2'-deoxyuridine and 5-iodo-2'-deoxyuridine, an iodinated analogue internal standard (IS), respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),min,12.5,147464,DB01101,Capecitabine
,15866500,recovery,"The average recovery was 81.5% and 78.6% for 2'-deoxyuridine and 5-iodo-deoxyuridine, respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),%,81.5,147465,DB01101,Capecitabine
,15866500,recovery,"The average recovery was 81.5% and 78.6% for 2'-deoxyuridine and 5-iodo-deoxyuridine, respectively.",Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866500/),%,78.6,147466,DB01101,Capecitabine
,16912527,response rate,The response rate was 25.0% (3 PR/12).,[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912527/),%,25.0,152993,DB01101,Capecitabine
,26917603,objective response rate,"The objective response rate in 73 treated patients was 38.4% (90% confidence interval, 28.8-48.6%), exceeding the prespecified boundary for an objective response rate > 20%.","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),%,38.4,153229,DB01101,Capecitabine
>,26917603,objective response rate,"The objective response rate in 73 treated patients was 38.4% (90% confidence interval, 28.8-48.6%), exceeding the prespecified boundary for an objective response rate > 20%.","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),%,20,153230,DB01101,Capecitabine
,26917603,progression-free survival,"After 6.5 months' median follow-up, median progression-free survival was 5.6 months (95% confidence interval, 4.6-8.2).","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),month,5.6,153231,DB01101,Capecitabine
,26917603,overall survival,"After 28.9 months' median follow-up, median overall survival was 30.5 months (95% confidence interval 25.2-not reached).","A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26917603/),month,30.5,153232,DB01101,Capecitabine
,9605432,AUCs,"In the three susceptible models, 5-FUra AUCs in tumors after capecitabine administration were 210 to 303 nmol x hr/g, whereas those after 5-FUra administration were 8.54 to 13.1 nmol x hr/g.","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],210 to 303,156816,DB01101,Capecitabine
,9605432,AUCs,"In the three susceptible models, 5-FUra AUCs in tumors after capecitabine administration were 210 to 303 nmol x hr/g, whereas those after 5-FUra administration were 8.54 to 13.1 nmol x hr/g.","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],8.54 to 13.1,156817,DB01101,Capecitabine
,9605432,AUC,"In the refractory model, WiDr, 5-FUra AUC in tumors after capecitabine administration was only 62.8 nmol x hr/g, although the level of the intermediate metabolite 5'-dFUrd was high (AUC: 695 nmol x hr/g).","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],62.8,156818,DB01101,Capecitabine
,9605432,AUC,"In the refractory model, WiDr, 5-FUra AUC in tumors after capecitabine administration was only 62.8 nmol x hr/g, although the level of the intermediate metabolite 5'-dFUrd was high (AUC: 695 nmol x hr/g).","Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9605432/),[h·nM] / [g],695,156819,DB01101,Capecitabine
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,17,158525,DB01101,Capecitabine
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,3,158526,DB01101,Capecitabine
,18525298,MTD,The MTD of epirubicin was 50 mg/m2.,"Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525298/),[mg] / [m2],50,165644,DB01101,Capecitabine
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,67.4,170229,DB01101,Capecitabine
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,62.1,170230,DB01101,Capecitabine
,28220020,OS,"Median OS was 67.4 weeks on RAM + CAP, 62.1 weeks on ICR + CAP, and 71.6 weeks on CAP (HRs: 1.833, p = .0283, RAM + CAP versus CAP; 1.468, p = .1550, ICR + CAP versus CAP).",Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28220020/),weeks,71.6,170231,DB01101,Capecitabine
,30599225,entrapment efficiency,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),%,20.53,173664,DB01101,Capecitabine
,30599225,diffusion coefficient,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),[cm2] / [s],2.83 × 10-11,173665,DB01101,Capecitabine
,30599225,diffusion exponent,"The LC-POSS MIPs had extended release of the template molecules over 13.4 h with entrapment efficiency of 20.53%, diffusion coefficient of 2.83 × 10-11 cm2 s-1, and diffusion exponent of 0.84.",Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30599225/),,0.84,173666,DB01101,Capecitabine
,23517808,MTD,The MTD of capecitabine was determined to be 825 mg/m(2) b.i.d.,Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23517808/),[mg] / [m],825,174735,DB01101,Capecitabine
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],40.0,176260,DB01101,Capecitabine
,24960402,Cmin,Mean pertuzumab Cmin at day 43 was 40.0 μg ml(-1) (s.d.: 17.3) in Arm A and 62.7 μg ml(-1) (29.1) in Arm B.,"A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24960402/),[μg] / [ml],62.7,176261,DB01101,Capecitabine
,16283312,Response rate,"Response rate was 30%, and disease stabilization rate was 64% (all dose levels included).",Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16283312/),%,30,177794,DB01101,Capecitabine
,16291583,response rate,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),%,17,179683,DB01101,Capecitabine
,16291583,time to progression (TTP),"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,5.4,179684,DB01101,Capecitabine
,16291583,survival,"The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2).",Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291583/),month,9.5,179685,DB01101,Capecitabine
,26718616,FUTP,"FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14.",Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),μM,1.0,181324,DB01101,Capecitabine
,26718616,FUTP,"FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14.",Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),μM,0.64 to 14,181325,DB01101,Capecitabine
,26718616,area under the FUTP concentration-time curve,The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h).,Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),h·μM,28,181326,DB01101,Capecitabine
,26718616,area under the FUTP concentration-time curve,The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h).,Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26718616/),h·μM,2.0,181327,DB01101,Capecitabine
higher,34347254,maximum plasma concentration (Cmax),"Reference scaled maximum plasma concentration (Cmax) was higher than 0.294, permitting use of RSABE.","Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34347254/),,0.294,186374,DB01101,Capecitabine
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB01101,Capecitabine
,15073108,elimination half-life (t(1/2)),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,0.5,198018,DB01101,Capecitabine
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,1.3,198019,DB01101,Capecitabine
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,1.2,198020,DB01101,Capecitabine
,15073108,t(1/2),"Ro 09-4889 has a short elimination half-life (t(1/2)) of 0.5 h, followed by metabolites 5'-deoxy-5-vinyluridine (5'-DVUR), 5'-deoxy-5-vinylcytidine (5'-DVCR), and 5-VU with t(1/2) of 1.3, 1.2, and 2 h, respectively.","Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),h,2,198021,DB01101,Capecitabine
,15073108,ED(50),The model-predicted ED(50) value was 100 mg.,"Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073108/),mg,100,198022,DB01101,Capecitabine
,29175408,t1/2,"The maximum and minimum mean t1/2 values of 5-fluorouracil were obtained when the drug was administered at 07:00h (23 HALO: 3.1±1.2h) and 13:00h (5 HALO: 1.5±0.6h), respectively.",Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),h,1.5,199781,DB01101,Capecitabine
,29175408,AUC0-∞,The AUC0-∞ value of 5-fluorouracil at 07:00h (23 HALO: 533.9±195.7μmol∙h/L) was 1.8-fold higher than the value at 13:00h (5 HALO: 302.5±157.1μmol∙h/L).,Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),[7μmol∙h] / [l],533.9,199782,DB01101,Capecitabine
,29175408,AUC0-∞,The AUC0-∞ value of 5-fluorouracil at 07:00h (23 HALO: 533.9±195.7μmol∙h/L) was 1.8-fold higher than the value at 13:00h (5 HALO: 302.5±157.1μmol∙h/L).,Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175408/),[1μmol∙h] / [l],302.5,199783,DB01101,Capecitabine
,25073394,total,"The use of voriconazole as the internal standard, combined with gradient elution and on-line wavelength switching, assured very high within- and between-run precision of results (relative standard deviation < 7.1% for lower limit of quantification) and enabled the reduction of the total chromatographic run time to 8 min.",Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073394/),,8,200334,DB01101,Capecitabine
,31955309,survival,Median survival of stable disease patients (14.4 months) was significantly longer than of progressive disease patients (6.5 months) and non-evaluable patients (2.3 months).,Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31955309/),month,14.4,203590,DB01101,Capecitabine
,31955309,survival,Median survival of stable disease patients (14.4 months) was significantly longer than of progressive disease patients (6.5 months) and non-evaluable patients (2.3 months).,Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31955309/),month,6.5,203591,DB01101,Capecitabine
,31955309,survival,Median survival of stable disease patients (14.4 months) was significantly longer than of progressive disease patients (6.5 months) and non-evaluable patients (2.3 months).,Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31955309/),month,2.3,203592,DB01101,Capecitabine
,31955309,T½,"MLP pharmacokinetics was stealth-like with long T½ (~1 day), slow clearance, and small volume of distribution (Vd).",Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31955309/),d,1,203593,DB01101,Capecitabine
,15939714,Response rate,Response rate in the phase II cohort was 42% [95% confidence interval (CI) 29% to 56%].,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),%,42,206007,DB01101,Capecitabine
,15939714,duration of response,Median duration of response was 7.7 months (95% CI 7.5-8.9).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,7.7,206008,DB01101,Capecitabine
,15939714,time to progression,Median time to progression was 8.3 months (95% CI 5.8-10).,A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15939714/),month,8.3,206009,DB01101,Capecitabine
,27390048,50% inhibitory,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),[ng] / [ml],0.00310,208880,DB01101,Capecitabine
,27390048,degradation rate constant,"The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively.",Pharmacokinetic model analysis of interaction between phenytoin and capecitabine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390048/),1/[d],0.0768,208881,DB01101,Capecitabine
,31138588,progression-free survival (PFS),The median progression-free survival (PFS) was 22.1 months (95% CI: 9.0-26.2 months).,"Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31138588/),month,22.1,210109,DB01101,Capecitabine
,11286326,time to reach peak concentration (tmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,2,217445,DB01101,Capecitabine
,11286326,peak plasma drug concentration (Cmax),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],3 to 4,217446,DB01101,Capecitabine
,11286326,elimination half-life (t(1/2)),"After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0.55 to 0.89 h].",Clinical pharmacokinetics of capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),h,0.55 to 0.89,217447,DB01101,Capecitabine
,11286326,Recovery,Recovery of drug-related material in urine and faeces is nearly 100%.,Clinical pharmacokinetics of capecitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),%,100,217448,DB01101,Capecitabine
,11286326,Cmax,Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[mg] / [l],0.22 to 0.31,217449,DB01101,Capecitabine
,11286326,area under the concentration-time curve (AUC),Plasma concentrations of the cytotoxic moiety fluorouracil are very low [with a Cmax of 0.22 to 0.31 mg/L and area under the concentration-time curve (AUC) of 0.461 to 0.698 mg x h/L].,Clinical pharmacokinetics of capecitabine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11286326/),[h·mg] / [l],0.461 to 0.698,217450,DB01101,Capecitabine
,12452753,elimination half-life,The elimination half-life of both drugs is 0.5-0.7 hours.,Fluorouracil for allergic reactions to capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452753/),h,0.5-0.7,222981,DB01101,Capecitabine
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.04 to 1.22,224474,DB01101,Capecitabine
,29453635,Trough plasma concentrations,Trough plasma concentrations ranged from 0.04 to 1.22 µg/ml after day 1 and from 0.01 to 2.4 µg/ml in the long-term assessment.,Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453635/),[μg] / [ml],0.01 to 2.4,224475,DB01101,Capecitabine
,16303864,response rate,"Objective responses were reported in 18 patients (three complete responses and 15 partial responses), yielding a response rate of 40.9% in the intention-to-treat population according to the investigator assessment.",Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303864/),%,40.9,227968,DB01101,Capecitabine
,10755317,concentration ratio,"The mean liver metastasis/healthy tissue 5-FU concentration ratio was 1.4 (P = 0.49, not statistically different).",Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,1.4,228855,DB01101,Capecitabine
exceeded,10755317,concentration ratios,The mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and ranged from 8 to 10 for other tissues.,Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,20,228856,DB01101,Capecitabine
exceeded,10755317,concentration ratios,The mean tissue/plasma 5-FU concentration ratios exceeded 20 for colorectal tumor and ranged from 8 to 10 for other tissues.,Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755317/),,8 to 10,228857,DB01101,Capecitabine
,27270460,progression-free survival (PFS),The median progression-free survival (PFS) was 10 months (range 2-36 months).,Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270460/),month,10,231854,DB01101,Capecitabine
,19935361,Time to first result,"Time to first result was 10 minutes, and 400 samples per hour could be quantitated from a standard curve stored for >30 days.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),min,10,233740,DB01101,Capecitabine
,19935361,Time to first result,"Time to first result was 10 minutes, and 400 samples per hour could be quantitated from a standard curve stored for >30 days.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),[samples] / [h],400,233741,DB01101,Capecitabine
<,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,1,233742,DB01101,Capecitabine
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,9.9,233743,DB01101,Capecitabine
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,0.05,233744,DB01101,Capecitabine
,19935361,Cross-reactivities,"Cross-reactivities for dihydro-5-FU, uracil, capecitabine, and tegafur were <1%, 9.9%, 0.05%, and 0.23%, respectively.",Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),%,0.23,233745,DB01101,Capecitabine
,19935361,limit of detection,The limit of detection was 52 ng/mL with a lower limit of quantitation of 86 ng/mL.,Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19935361/),[ng] / [ml],52,233746,DB01101,Capecitabine
,10555122,tmax,"Based on the radioactivity measurements of drug-related material, absorption is rapid (tmax 0.25-1.5 hours) followed by a rapid biphasic decline.",A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10555122/),h,0.25-1.5,236321,DB01101,Capecitabine
,30544058,response rate,The response rate was 42.3% (95% confidence interval (CI) 28.7-56.8%) with 7.7% complete and 34.6% partial responses.,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),%,42.3,238236,DB01101,Capecitabine
,30544058,progression free survival,Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months).,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),month,10.8,238237,DB01101,Capecitabine
,30544058,overall survival,Median progression free survival was 10.8 months (95% CI 6.9-14.7 months) and median overall survival 27.6 months (95% CI 20.4-34.8 months).,Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30544058/),month,27.6,238238,DB01101,Capecitabine
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,6.4,242929,DB01101,Capecitabine
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,5.5-8.0,242930,DB01101,Capecitabine
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,46.7,242931,DB01101,Capecitabine
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,43.5-45.5,242932,DB01101,Capecitabine
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,0.546,246562,DB01101,Capecitabine
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,0.892,246563,DB01101,Capecitabine
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,1.562,246564,DB01101,Capecitabine
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,4.736,246565,DB01101,Capecitabine
,30964613,sampling times,"The optimal sampling times were 0.546, 0.892, 1.562, 4.736 and 8 hours after the administration of the drug.",Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30964613/),h,8,246566,DB01101,Capecitabine
,32559325,Circ0,"System- (Circ0 = 3.54 × 109 cells/mL, MTT = 204 hours and γ = 6.0 × 10-2 ) and drug-related (slope [SLP] = 3.1 × 10-2 mL/mg).",Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32559325/),[cells] / [ml],3.54 ×,247806,DB01101,Capecitabine
,32559325,MTT,"System- (Circ0 = 3.54 × 109 cells/mL, MTT = 204 hours and γ = 6.0 × 10-2 ) and drug-related (slope [SLP] = 3.1 × 10-2 mL/mg).",Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32559325/),h,204,247807,DB01101,Capecitabine
,33417061,first-order elimination (ke,"The PK of intracellular FUTP was described by an one-compartment model with first-order elimination (ke,FUTP was 0.028 h-1 (95% confidence interval 0.022-0.039)) where the FUTP influx rate was proportional to the 5-FU plasma concentrations.",Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33417061/),1/[h],0.028,248439,DB01101,Capecitabine
,25584489,OS,"Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7-9.7) vs 4.4 (2.9-4.9) and 5.5 (4.2-6.8) months) and OS (13.4 (10.6-18.6) vs 5.7 (4.7-10.2) and 8.1 (6.9-11.1) months) without increased toxicity.",Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25584489/),month,13,251137,DB01101,Capecitabine
,25584489,OS,"Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7-9.7) vs 4.4 (2.9-4.9) and 5.5 (4.2-6.8) months) and OS (13.4 (10.6-18.6) vs 5.7 (4.7-10.2) and 8.1 (6.9-11.1) months) without increased toxicity.",Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25584489/),month,5.,251138,DB01101,Capecitabine
,25584489,OS,"Among MET-positive patients, higher rilotumumab exposure, vs placebo and low exposure, was associated with improved median PFS (80% CI: 7.0 (5.7-9.7) vs 4.4 (2.9-4.9) and 5.5 (4.2-6.8) months) and OS (13.4 (10.6-18.6) vs 5.7 (4.7-10.2) and 8.1 (6.9-11.1) months) without increased toxicity.",Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25584489/),month,8,251139,DB01101,Capecitabine
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,71,252127,DB01101,Capecitabine
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,77,252128,DB01101,Capecitabine
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,42,252129,DB01101,Capecitabine
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,62,252130,DB01101,Capecitabine
,30783204,MTD,The MTD of eribulin was 1.6 mg/m2 day 1 for schedule 1 and 1.4 mg/m2 days 1 and 8 for schedule 2.,"A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),[mg] / [m2],1.6,257361,DB01101,Capecitabine
,30783204,MTD,The MTD of eribulin was 1.6 mg/m2 day 1 for schedule 1 and 1.4 mg/m2 days 1 and 8 for schedule 2.,"A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),mg,1.4,257362,DB01101,Capecitabine
,30783204,ORR,"ORR in phase 2 (eribulin 1.4 mg/m2 days 1, 8 plus capecitabine) was 43% and median PFS 7.2 months.","A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),%,43,257363,DB01101,Capecitabine
,30783204,PFS,"ORR in phase 2 (eribulin 1.4 mg/m2 days 1, 8 plus capecitabine) was 43% and median PFS 7.2 months.","A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30783204/),month,7,257364,DB01101,Capecitabine
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,0.88,257590,DB01101,Capecitabine
,17195945,T(max),"However, SN-38 T(max) was longer on Day 8 (0.88 h vs. 1.23 h, p = 0.012).",Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195945/),h,1.23,257591,DB01101,Capecitabine
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,105-115,263258,DB01101,Capecitabine
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,92.6-101,263259,DB01101,Capecitabine
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,94.0-100,263260,DB01101,Capecitabine
,25808944,extraction recoveries,"The mean extraction recoveries were within 105-115%, 92.6-101%, 94.0-100%, and 85.1-99.9% for Cape, DFCR, DFUR, and 5-FU, respectively.",Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808944/),%,85.1-99.9,263261,DB01101,Capecitabine
,25687867,response duration,Median response duration was 9.1 months; median progression-free survival was 3.8 months.,Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687867/),month,9.1,266502,DB01101,Capecitabine
,25687867,progression-free survival,Median response duration was 9.1 months; median progression-free survival was 3.8 months.,Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687867/),month,3.8,266503,DB01101,Capecitabine
,28973403,progression-free survival,"In Part 2, five of eight patients (63%) with measureable disease at baseline had a partial response and two patients (25%) had stable disease; median (95% CI) progression-free survival was 7.0 (2.4-15.4) months; overall survival was 18.2 (5.6-20.4) months.",A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28973403/),month,7.0,267854,DB01101,Capecitabine
,28973403,overall survival,"In Part 2, five of eight patients (63%) with measureable disease at baseline had a partial response and two patients (25%) had stable disease; median (95% CI) progression-free survival was 7.0 (2.4-15.4) months; overall survival was 18.2 (5.6-20.4) months.",A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28973403/),month,18.2,267855,DB01101,Capecitabine
,29488048,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],11.51,273614,DB01101,Capecitabine
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],2.45,273615,DB01101,Capecitabine
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],6.43,273616,DB01101,Capecitabine
,29488048,Cmax,"Maximum plasma concentrations (Cmax) of capecitabine (11.51 ± 9.73 μg/ml) occurred at 0.5 h, whereas the Cmax of 5'-deoxy-5-fluorocytidine (5'-DFCR; 2.45 ± 2.93 μg/ml), 5'-deoxy-5-fluorouridine (5'-DFUR; 6.43 ± 8.2 μg/ml), and 5-fluorouracil (5-FU; 0.24 ± 0.16 μg/ml) were found at 1 h, 1.5 h and 1 h, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[μg] / [ml],0.24,273617,DB01101,Capecitabine
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],21.30,273618,DB01101,Capecitabine
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],5.2,273619,DB01101,Capecitabine
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],19.59,273620,DB01101,Capecitabine
,29488048,AUCs,"Capecitabine, 5'-DFCR, 5'-DFUR and 5-FU AUCs at day 1 were 21.30 ± 10.78, 5.2 ± 4.6, 19.59 ± 3.83 and 0.66 ± 0.77 hxμg/ml, respectively.",Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488048/),[h·μg] / [ml],0.66,273621,DB01101,Capecitabine
